No products in the cart.

Anti-Podoplanin antibody

SKU Product Brand Unit Availability Price Quantity  
AB-06-3635
Anti-Podoplanin antibody
Erpan Tech In stock

Specifications        

Product Cat#: AB-06-3635
Product type: Primary antibody
Antigen: Podoplanin
Immunogen: Recombinant protein
Species immunized: Rabbit
Isotype: IgG
Applications: Western Blot (1:2000-1:5000); Immunohistochemistry (1:50-1:200)
Reactivity: Human
Clonality (clone number): Monoclonal (JM31-21)
Form: Liquid
Buffer: Tris-HCl buffer (pH7.4), 1% BSA, 40% Glycerol, 0.05% NaN3.
Concentration: 1 mg/ml
Purity: Protein A affinity purified
Storage: Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles.
Alternative names: Aggrus antibody
Glycoprotein 36 KD antibody
Glycoprotein 36 antibody
gp 36 antibody
GP 38 antibody
GP 40 antibody
gp36 antibody
GP38 antibody
GP40 antibody
HT1A 1 antibody
HT1A1 antibody
hT1alpha 1 antibody
hT1alpha 2 antibody
hT1alpha1 antibody
hT1alpha2 antibody
Lung Type I Cell Membrane Associated Glycoprotein antibody
Lung Type I Cell Membrane Associated Glycoprotein Isoform a antibody
Lung Type I Cell Membrane Associated Glycoprotein T1A 2 antibody
OTS 8 antibody
OTS8 antibody
OTTHUMP00000009640 antibody
OTTHUMP00000044504 antibody
PA2.26 antibody
PA2.26 antigen antibody
Pdpn antibody
PDPN_HUMAN antibody
Podoplanin antibody
PSEC0003 antibody
PSEC0025 antibody
T1 Alpha antibody
T1 ALPHA GENE antibody
T1-Alpha antibody
T1A 2 antibody
T1A antibody
TI1A antibody
TIA 2 antibody
Show More

Target information

Mediates effects on cell migration and adhesion through its different partners. During development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation (PubMed:14522983, PubMed:15231832, PubMed:17616532, PubMed:18215137, PubMed:17222411). Interaction with CD9, on the contrary, attenuates platelet aggregation induced by PDPN (PubMed:18541721). Through MSN or EZR interaction promotes epithelial-mesenchymal transition (EMT) leading to ERZ phosphorylation and triggering RHOA activation leading to cell migration increase and invasiveness (PubMed:17046996, PubMed:21376833).

Provider

Erpantech Laboratory

download

MSDS-AB-06-3635.pdf (113 downloads)